{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:02Z","timestamp":1786991222371,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaad.2021.11.065","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T17:38:09Z","timestamp":1643823489000},"page":"1207-1226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics"],"prefix":"10.1016","volume":"86","author":[{"given":"Fiorinda F.","family":"Muhaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1586\/14787210.2015.1032939","article-title":"Azole antifungals: 35 years of invasive fungal infection management","volume":"13","author":"Allen","year":"2015","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"10","key":"10.1016\/j.jaad.2021.11.065_bib2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jaad.2021.11.065_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019752","article-title":"Mechanisms of antifungal drug resistance","volume":"5","author":"Cowen","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jaad.2021.11.065_bib6","series-title":"Comprehensive Dermatologic Drug Therapy","first-page":"99","article-title":"Systemic antifungal agents","author":"Wolverton","year":"2020"},{"issue":"1","key":"10.1016\/j.jaad.2021.11.065_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: Spectrum of Activity, Pharmacology, and Clinical Indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: treatment and prevention of recurrence","volume":"80","author":"Lipner","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0002-9343(93)90280-3","article-title":"Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group","volume":"95","author":"Sharkey-Mathis","year":"1993","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2017.06.032","article-title":"Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation","volume":"77","author":"Kuklinski","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.11.065_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ajt.13431","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients","volume":"16","author":"Mansh","year":"2016","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ijd.14238","article-title":"Cutaneous effects associated with fluconazole in patients treated for coccidioidomycosis","volume":"58","author":"Brewer","year":"2019","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.11.065_bib14","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jphp.12780","article-title":"Echinocandins in antifungal pharmacotherapy","volume":"69","author":"Patil","year":"2017","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"10.1016\/j.jaad.2021.11.065_bib15","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1128\/AAC.00563-06","article-title":"Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for \u03b2-1,6-Glucan synthesis inhibition by caspofungin","volume":"50","author":"Stevens","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaad.2021.11.065_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12831","article-title":"Mechanisms of echinocandin antifungal drug resistance","volume":"1354","author":"Perlin","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"14","key":"10.1016\/j.jaad.2021.11.065_bib17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-014-0286-5","article-title":"Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management","volume":"74","author":"Perlin","year":"2014","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1574-6968.2007.00710.x","article-title":"Analysis of Trichophyton rubrum gene expression in response to cytotoxic drugs","volume":"271","author":"Pai\u00c3\u00a3o","year":"2007","journal-title":"FEMS Microbiol Lett"},{"issue":"7","key":"10.1016\/j.jaad.2021.11.065_bib21","first-page":"CD010031","article-title":"Oral antifungal medication for toenail onychomycosis","volume":"7","author":"Kreijkamp-Kaspers","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2021.11.065_bib22","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.fgb.2019.103255","article-title":"Antifungal resistance in dermatophytes: recent trends and therapeutic implications","volume":"132","author":"Khurana","year":"2019","journal-title":"Fungal Genet Biol"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaad.2016.08.061","article-title":"Systemic antifungal therapy for tinea capitis in children: an abridged Cochrane Review","volume":"76","author":"Chen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4 Pt 2","key":"10.1016\/j.jaad.2021.11.065_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0190-9622(90)70288-S","article-title":"Pharmacology of the allylamines","volume":"23","author":"Birnbaum","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.11.065_bib25","series-title":"Comprehensive Dermatologic Drug Therapy","first-page":"480","article-title":"Topical antifungal agents","author":"Wolverton","year":"2020"},{"issue":"16","key":"10.1016\/j.jaad.2021.11.065_bib26","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1517\/14656560903307462","article-title":"Terbinafine: a pharmacological and clinical review","volume":"10","author":"Krishnan-Natesan","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1016\/j.jaad.2021.11.065_bib29","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1128\/AAC.49.12.5146-5148.2005","article-title":"Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways","volume":"49","author":"Wiederhold","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib30","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jaad.2021.11.065_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.11.065_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: mechanisms and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"issue":"5","key":"10.1016\/j.jaad.2021.11.065_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10096-013-2009-3","article-title":"Candida glabrata: a review of its features and resistance","volume":"33","author":"Rodrigues","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.jaad.2021.11.065_bib34","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.00064-14","article-title":"Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by fluconazole","volume":"58","author":"Vasicek","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 6","key":"10.1016\/j.jaad.2021.11.065_bib35","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jaad.2021.11.065_bib36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/myc.12904","article-title":"Candida auris-the growing menace to global health","volume":"62","author":"Lone","year":"2019","journal-title":"Mycoses"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib37","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/j.1365-4632.2012.05689.x","article-title":"Pityriasis versicolor: a case of resistance to treatment","volume":"53","author":"Helou","year":"2014","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.11.065_bib38","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archdermatol.2010.259","article-title":"Pityriasis versicolor: A systematic review of interventions","volume":"146","author":"Hu","year":"2010","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04203","article-title":"Susceptibilities of Malassezia strains from pityriasis versicolor, Malassezia folliculitis and seborrheic dermatitis to antifungal drugs","volume":"6","author":"Wang","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jaad.2021.11.065_bib40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fmicb.2018.01108","article-title":"Dermatophyte resistance to antifungal drugs: mechanisms and prospectus","volume":"9","author":"Martinez-Rossi","year":"2018","journal-title":"Front Microbiol"},{"issue":"5-6","key":"10.1016\/j.jaad.2021.11.065_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11046-008-9110-7","article-title":"Antifungal resistance mechanisms in dermatophytes","volume":"166","author":"Martinez-Rossi","year":"2008","journal-title":"Mycopathologia"},{"issue":"11","key":"10.1016\/j.jaad.2021.11.065_bib42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jdcr.2020.05.025","article-title":"Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat","volume":"6","author":"Gu","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/idoj.IDOJ_146_19","article-title":"Antifungal drug susceptibility testing of dermatophytes: laboratory findings to clinical implications","volume":"10","author":"Dogra","year":"2019","journal-title":"Indian Dermatol Online J"},{"issue":"10","key":"10.1016\/j.jaad.2021.11.065_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01126-19","article-title":"Emerging terbinafine resistance in trichophyton: clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection","volume":"63","author":"Saunte","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40257-020-00580-6","article-title":"The growing problem of antifungal resistance in onychomycosis and other superficial mycoses","volume":"22","author":"Gupta","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.11.065_bib46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4103\/ijd.IJD_131_17","article-title":"Antifungal resistance in dermatology","volume":"63","author":"Pai","year":"2018","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13693780500220449","article-title":"Martinez-Rossi NMMolecular cloning and characterization of a novel ABC transporter gene in the human pathogen Trichophyton rubrum","volume":"44","author":"Cervelatti","year":"2006","journal-title":"Med Mycol"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00253-009-1908-9","article-title":"Transcriptional profiles of response to terbinafine in Trichophyton rubrum","volume":"82","author":"Zhang","year":"2009","journal-title":"Appl Microbiol Biotechnol"},{"issue":"Supplement_3","key":"10.1016\/j.jaad.2021.11.065_bib49","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib51","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaad.2013.03.021","article-title":"A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis","volume":"69","author":"Sigurgeirsson","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.11.065_bib52","article-title":"A Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail","author":"Elewski","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2021.11.065_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","article-title":"Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy","volume":"14","author":"Sofjan","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"10.1016\/j.jaad.2021.11.065_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jim\u00e9nez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jaad.2021.11.065_bib55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/jof6010028","article-title":"Aspiring antifungals: review of current antifungal pipeline developments","volume":"6","author":"Gintjee","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"9","key":"10.1016\/j.jaad.2021.11.065_bib57","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/jamadermatol.2019.1541","article-title":"Topical itraconazole for the treatment of basal cell carcinoma in patients with basal cell nevus syndrome or high-frequency basal cell carcinomas: A Phase 2, open-label, placebo-controlled trial","volume":"155","author":"Sohn","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00341-19","article-title":"In\u00a0vitro\u00a0activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida\u00a0albicans","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/em.21839","article-title":"Unveiling Benznidazole\u2019s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi","volume":"55","author":"Raj\u00e3o","year":"2014","journal-title":"Environ Mol Mutagen"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jis331","article-title":"Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population","volume":"206","author":"Mejia","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.11.065_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molbiopara.2014.01.002","article-title":"Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert","volume":"193","author":"Campos","year":"2014","journal-title":"Mol Biochem Parasitol"},{"issue":"10","key":"10.1016\/j.jaad.2021.11.065_bib63","first-page":"2471","article-title":"Free radical metabolism of antiparasitic agents","volume":"45","author":"Docampo","year":"1986","journal-title":"Fed Proc"},{"issue":"13","key":"10.1016\/j.jaad.2021.11.065_bib64","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and Benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib66","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0001-706X(01)00177-2","article-title":"Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter","volume":"80","author":"de Koning","year":"2001","journal-title":"Acta Trop"},{"issue":"11","key":"10.1016\/j.jaad.2021.11.065_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006980","article-title":"Insights into antitrypanosomal drug mode-of-action from cytology-based profiling","volume":"12","author":"Thomas","year":"2018","journal-title":"PLOS Negl Trop Dis"},{"issue":"Supp 1","key":"10.1016\/j.jaad.2021.11.065_bib68","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitol Res"},{"issue":"24","key":"10.1016\/j.jaad.2021.11.065_bib69","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1074\/jbc.RA120.012355","article-title":"Suramin exposure alters cellular metabolism and mitochondrial energy production in African trypanosomes","volume":"295","author":"Zoltner","year":"2020","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib70","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pt.2018.04.002","article-title":"Melarsoprol resistance in African trypanosomiasis","volume":"34","author":"Fairlamb","year":"2018","journal-title":"Trends Parasitol"},{"issue":"5","key":"10.1016\/j.jaad.2021.11.065_bib71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-3156.2001.00725.x","article-title":"Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment","volume":"6","author":"Burri","year":"2001","journal-title":"Trop Med Int Health"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib72","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1406.071266","article-title":"High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo","volume":"14","author":"Robays","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","article-title":"Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story","volume":"29","author":"Baker","year":"2013","journal-title":"Trends Parasitol"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib74","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/AAC.27.6.916","article-title":"Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate","volume":"27","author":"Berman","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jaad.2021.11.065_bib75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/AAC.50.1.88-95.2006","article-title":"Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase","volume":"50","author":"Carter","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0974-777X.62887","article-title":"Drug resistance in leishmaniasis","volume":"2","author":"Chakravarty","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.jaad.2021.11.065_bib77","series-title":"spp.to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. Leishmaniasis","first-page":"711","article-title":"The in\u00a0vitro susceptibility of macrophages infected with amastigotes of Leishmania","author":"Allen","year":"1998"},{"issue":"5","key":"10.1016\/j.jaad.2021.11.065_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/jac\/35.5.577","article-title":"The sensitivity of Leishmania species to aminosidine","volume":"35","author":"Neal","year":"1995","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib79","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4269\/ajtmh.1981.30.566","article-title":"Activity of imidazoles against Leishmania tropica in human macrophage cultures","volume":"30","author":"Berman","year":"1981","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib80","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib81","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/516526","article-title":"Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis","volume":"176","author":"Sundar","year":"1997","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2021.11.065_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib83","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4155\/fmc.15.11","article-title":"What is the mechanism of action\u00a0of praziquantel and how might resistance strike?","volume":"7","author":"Cupit","year":"2015","journal-title":"Future Med Chem"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib84","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","article-title":"Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis","volume":"21","author":"Doenhoff","year":"2008","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"10.1016\/j.jaad.2021.11.065_bib85","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/0929867325666180926145537","article-title":"The mechanism of action of praziquantel: can new drugs exploit similar mechanisms?","volume":"27","author":"Thomas","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaad.2021.11.065_bib89","article-title":"Prestium Pharma, Inc, DENAVIR (penciclovir). U.S. Food and Drug Administration website","year":"2013","journal-title":"Revised September"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib90","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jaad.2021.11.065_bib91","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1517\/13543776.2014.927442","article-title":"Anti-herpesvirus agents: a patent and literature review (2003 to present)","volume":"24","author":"Skore\u0144ski","year":"2014","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib92","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/106002809703100211","article-title":"Valacyclovir","volume":"31","author":"Acosta","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2021.11.065_bib94","series-title":"Comprehensive Dermatologic Drug Therapy","first-page":"114","article-title":"Systemic antiviral agents","author":"Wolverton","year":"2020"},{"key":"10.1016\/j.jaad.2021.11.065_bib95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-981-10-7230-7_6","article-title":"Antiviral drugs against alphaherpesvirus","volume":"1045","author":"Shiraki","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib96","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/095632029300400201","article-title":"Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir","volume":"4","author":"Hodge","year":"1993","journal-title":"Antivir Chem Chemother"},{"issue":"9","key":"10.1016\/j.jaad.2021.11.065_bib98","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/106002809603000913","article-title":"Famciclovir for treatment of herpesvirus infections","volume":"30","author":"Luber","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib99","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOT.0000000000000541","article-title":"Drug-resistant cytomegalovirus: clinical implications of specific mutations","volume":"23","author":"Razonable","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"issue":"20","key":"10.1016\/j.jaad.2021.11.065_bib101","first-page":"9530","article-title":"Distribution and effects of amino acid changes in drug-resistant \u03b1 and \u03b2 herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jaad.2021.11.065_bib102","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.4081\/dr.2018.7749","article-title":"Foscarnet-induced genital lesions: an overview with a case report","volume":"10","author":"Adalsteinsson","year":"2018","journal-title":"Dermatol Rep"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2021.11.065_bib103","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(98)70046-5","article-title":"Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects","volume":"39","author":"Zabawski","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib104","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.jaad.2021.11.065_bib105","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jdcr.2015.09.019","article-title":"Two cases of trichodysplasia spinulosa responsive to compounded topical cidofovir 3% cream","volume":"1","author":"Leitenberger","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2021.11.065_bib106","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/516542","article-title":"A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS","volume":"176","author":"Lalezari","year":"1997","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.jaad.2021.11.065_bib107","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/archderm.147.12.1462","article-title":"Chronic acyclovir-resistant HSV-2 ulcer in an immunosuppressed patient treated with topical cidofovir","volume":"147","author":"Evans","year":"2011","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.11.065_bib108","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2021.11.065_bib109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.jaad.2021.11.065_bib110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11899-020-00557-6","article-title":"Moving past ganciclovir and foscarnet: advances in CMV therapy","volume":"15","author":"Hakki","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jaad.2021.11.065_bib111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.01.013","article-title":"HSV antivirals\u2014current and future treatment options","volume":"18","author":"Birkmann","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"3","key":"10.1016\/j.jaad.2021.11.065_bib112","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.jaad.2021.11.065_bib113","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/jmv.23329","article-title":"Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial","volume":"84","author":"Tyring","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2021.11.065_bib114","author":"Wald"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:03:16Z","timestamp":1759273396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0190962222001839"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.11.065","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.11.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(22)00621-1","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}